Tim Smith

In these new findings, investigators highlight phase 1 research into ritlecitinib for patients aged 6 to 12 years with alopecia areata.

These data point to inaccessibility, distance from providers, and insurance-related barriers as obstacles to mental health improvement among children with atopic dermatitis.

In this retrospective analysis, investigators in Japan highlighted the prevalence and incidence of comorbidities in those with atopic dermatitis, psoriasis, alopecia areata, and vitiligo.

The drug given this designation, known as rezpegaldesleukin, is indicated for adult and pediatric patients aged 12 years and older with atopic dermatitis.

This announcement by INmune Bio, Inc., follows positive findings in the MissionEB clinical trial evaluating CORDStrom for treatment of recessive dystrophic epidermolysis bullosa.

In this study, investigators highlighted factors associated with active hidradenitis suppurativa over the age of 50 such as smoking, male gender, and later onset of disease.

In this analysis, investigators conclude that health-related quality of life and clinical burdens are greater among patients with hidradenitis suppurativa and draining tunnels.

These data suggest that the Family Acceptance and Commitment Therapy-based Eczema Management Program, or FACT-EMP, may be helpful to children with atopic dermatitis.

These data suggest that dupilumab’s drug survival rate at 12 and 24 months is greater than that of upadacitinib and tralokinumab among patients with atopic dermatitis.

In this analysis, investigators concluded that dupilumab may be a viable treatment choice for pregnant or breastfeeding mothers with atopic dermatitis.

This segment of Hebert’s interview features a discussion regarding the safety profile of tapinarof 1% for patients aged 2 years and older with atopic dermatitis.

These data point to milestone event frequency and prevalence by subtype of RDEB, highlighting such events as dysphagia and squamous cell carcinoma.

Adelaide Hebert, MD, discusses the impact of the recent approval for tapinarof cream in the management of atopic dermatitis.

These data suggest a wearable haptic feedback sensor powered by artificial intelligence may function as a supportive therapeutic device for those with atopic dermatitis.

These new data were announced by LEO Pharma following the phase 3 DELTA TEEN trial, assessing delgocitinib 20mg/g cream for chronic hand eczema (CHE).

In this segment of January's Lungcast episode, guests discussed the Global Lung Function Initiative (GLI) network, lung function testing, and the use of race-based normal values.

Targeted anti-inflammatory treatment may be reasonable for addressing the causes ofsystemic inflammation in those with severe junctional and dystrophic epidermolysis bullosa.

This study highlights upadacitinib’s efficacy across clinical phenotypes for those with atopic dermatitis, noting any differences in response rates among patients.

This review of January 2025 in dermatology news highlights new developments in the treatment of conditions such as psoriasis, alopecia areata, and atopic dermatitis.

This literature review points to a variety of research into differences in the diagnosis and treatment of patients with psoriasis and skin of color compared to non-skin of color patients.

This literature review explored the topic of hidradenitis suppurativa management during pregnancy and lactation, highlighting data available on this topic.

The FDA approval of suzetrigine, a non-opioid pain signal inhibitor, may help address the needs of patients with moderate-to-severe acute pain.

These data may provide useful information for additional studies on the pathogenesis and treatments of urticaria-related psoriasis.

In this study, several predictive factors for positive alopecia areata outcomes after baricitinib therapy were identified, including female sex and a lower SALT score before treatment.

In this analysis, investigators explored whether dietary sodium intake was linked with psoriasis and whether any subgroups of patients were more likely to report salt-sensitive psoriasis.

These real-world, 52-week data demonstrate that deucravacitinib is effective for patients in various age brackets, though BMI has a slight impact on its efficacy.

These findings highlight dupilumab’s use as a potential treatment option for individuals with prurigo nodularis.

The findings in this analysis indicate that a balanced, infrequent diet including proteins and fats may provide individuals with a potential strategy for management of atopic dermatitis.

This month’s Lungcast features a discussion on pulmonary function tests and the controversial practice of using race-based normal values.

These findings suggest the ACORN PtGA tool may be effective as an alternative option for acne assessment when a clinician is unavailable.